POSITION SUMMARY
The Amunix VP/SVP of Research will provide research leadership across discovery and preclinical research, be responsible for all Preclinical Development Sciences functions (in vitro and in vivo pharmacology, translational biology, and toxicology), and provide expertise and insight into critical aspects of target credentialing in immuno-oncology and inflammation. In collaboration with the company’s Chief Technology Officer (CTO), this individual will establish the Company's strategic research plan in support of the Company's portfolio strategy. He/she will translate the strategy into action from basic research through completion of IND enabling studies and finalization of regulatory documents enabling FIH studies. Working with the CTO, the VP/SVP of Research will oversee the design of the organization’s products and investigate new technologies. The VP/SVP of Research will provide guidance on scientific-and immunology-related matters to the leaders across the company, outside collaborators, and scientific/regulatory agencies.
ESSENTIAL FUNCTIONS
REPORTING RELATIONSHIPS:
The VP/SVP of Research will report directly to Darcy Mootz, Ph.D, the Head of Amunix. This position will have all Preclinical Development Sciences functions (in vitro and in vivo pharmacology, translational biology, and toxicology) reporting into it.
ABOUT AMUNIX
Amunix is a Sanofi Center of Excellence that is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors. Our goal is to improve the lives of people with cancer in pursuit of cures through the development and commercialization of breakthrough therapies that harness the immune system. We have designed XTEN, a validated therapeutic half-life extension technology. Our current focus is Pro-XTEN, a next-generation protease activated pro-drug platform, which enables selective activation of potent cancer therapies in the tumor microenvironment. This overcomes a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Amunix’s lead programs employ the Pro-XTEN technology to enhance the safety profile of T cell engagers. XPATs (XTENylated Protease-Activated T Cell Engagers) have the potential to make off-the-shelf therapies redirecting T cells to solid tumors a reality.
Amunix provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, disability, or genetics. In addition to federal law requirements, Amunix complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfers, leaves of absence, compensation, and training.
Please be advised that Amunix requires that all employees have the COVID-19 vaccination to work onsite, unless the employee has an approved medical or religious exemption.
Safely Harnessing the Immune System to Conquer Cancer
Subscribe to Rise newsletter